Literature DB >> 10669677

Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA.

M T van Rens1, A B de la Rivière, H R Elbers, J M van Den Bosch.   

Abstract

STUDY
OBJECTIVES: Staging and classification in lung cancer are important for both patient management and clinical research. Results of survival after resection in patients with primary non-small cell lung cancer (NSCLC) are analyzed in order to validate recent refinements of the staging system.
DESIGN: Retrospective study; period from 1970 to 1992; follow-up > or = 5 years. PATIENTS: A total of 2,361 previously untreated patients who underwent resection for stage I, II, or IIIA primary NSCLC. MEASUREMENTS: Survival was estimated from the date of operation using the Kaplan-Meier survival analysis method. Deaths within 30 days of operation were excluded. Survival comparisons of different surgical-pathologic TNM classification (based on pathologic examination of resected specimens) as well as further discriminative factors were analyzed by log-rank test.
RESULTS: Postoperative death occurred in 3.9% of patients. For survival analyses, 2,263 patients were included. The overall 5-year survival was 937/2,263 (41.4%). Five-year survival in stage IA was 255/404 (63%); in stage IB, 367/797 (46%); in stage IIA, 43/83 (52%); in stage IIB, 210/642 (33%); and in stage IIIA, 63/337 (19%). No significant difference in survival was demonstrated between stages IB and IIA. Until 4 years after surgery, age at operation did not influence survival; after 5 years, patients > 65 years old had a significantly lower survival.
CONCLUSION: The TNM staging system accurately reflects the prognosis in primary NSCLC, but some stage definitions can be discussed. Despite the fact that the staging system is built on clinical data, the present analysis, which includes postsurgical data, confirms the similar survival of patients with T2N0M0 and T1N1M0. These results also stress the use of two separate substages, especially because these patients are offered surgery when possible.

Entities:  

Mesh:

Year:  2000        PMID: 10669677     DOI: 10.1378/chest.117.2.374

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  57 in total

1.  ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis.

Authors:  Jingwei Jiang; Xiaohua Liang; Xinli Zhou; Ruofan Huang; Zhaohui Chu; Qiong Zhan
Journal:  Mol Biol Rep       Date:  2012-06       Impact factor: 2.316

2.  A new PET/CT volumetric prognostic index for non-small cell lung cancer.

Authors:  Hao Zhang; Kristen Wroblewski; Yulei Jiang; Bill C Penney; Daniel Appelbaum; Cassie A Simon; Ravi Salgia; Yonglin Pu
Journal:  Lung Cancer       Date:  2015-04-09       Impact factor: 5.705

3.  (18)F-FDG-PET/CT in the assessment of pulmonary solitary nodules: comparison of different analysis methods and risk variables in the prediction of malignancy.

Authors:  Ober van Gómez López; Ana María García Vicente; Antonio Francisco Honguero Martínez; Germán Andrés Jiménez Londoño; Carlos Hugo Vega Caicedo; Pablo León Atance; Ángel María Soriano Castrejón
Journal:  Transl Lung Cancer Res       Date:  2015-06

4.  Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.

Authors:  Shengri Liao; Bill C Penney; Kristen Wroblewski; Hao Zhang; Cassie A Simon; Rony Kampalath; Ming-Chi Shih; Naoko Shimada; Sheng Chen; Ravi Salgia; Daniel E Appelbaum; Kenji Suzuki; Chin-Tu Chen; Yonglin Pu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-23       Impact factor: 9.236

5.  Follow-up or Surveillance (18)F-FDG PET/CT and Survival Outcome in Lung Cancer Patients.

Authors:  Alexander J Antoniou; Charles Marcus; Abdel K Tahari; Richard L Wahl; Rathan M Subramaniam
Journal:  J Nucl Med       Date:  2014-04-28       Impact factor: 10.057

6.  The usefulness of combined diagnostic CT and (99m)Tc-octreotide somatostatin receptor SPECT/CT imaging on pulmonary nodule characterization in patients.

Authors:  Liwei Wang; Xindao Yin; Feng Wang; Jianping Gu; Lingquan Lu; Qianzhi Wu; Baozhong Shen; Xiao-Feng Li
Journal:  Cancer Biother Radiopharm       Date:  2013-10-05       Impact factor: 3.099

7.  Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma.

Authors:  Young Joo Lee; In Kyu Park; Moo-Suk Park; Hye Jin Choi; Byoung Chul Cho; Kyung Young Chung; Se Kyu Kim; Joon Chang; Jin Wook Moon; Hoguen Kim; Sung Ho Choi; Joo-Hang Kim
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-11       Impact factor: 4.553

8.  Clinicopathological characteristics of resected adenosquamous cell carcinoma of the lung: risk of coexistent double cancer.

Authors:  Hidetaka Uramoto; Sohsuke Yamada; Takeshi Hanagiri
Journal:  J Cardiothorac Surg       Date:  2010-10-29       Impact factor: 1.637

9.  Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma.

Authors:  Peng Xie; Jin-Bo Yue; Han-Xi Zhao; Xin-Dong Sun; Li Kong; Zheng Fu; Jin-Ming Yu
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-20       Impact factor: 4.553

10.  Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS).

Authors:  Richard J Gralla; Martin J Edelman; Frank C Detterbeck; Thierry M Jahan; David M Loesch; Steven A Limentani; Ramaswamy Govindan; Guangbin Peng; Matthew J Monberg; Coleman K Obasaju; Mark A Socinski
Journal:  Support Care Cancer       Date:  2008-09-10       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.